Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

$144.24

-3.32 (-2.25%)

(As of 07/26/2024 ET)

Sarepta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 18 Analyst Ratings

Based on 18 Wall Street analysts who have issued ratings for Sarepta Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for SRPT.

Consensus Price Target

$187.72
30.15% Upside

High Forecast	$235.00
Average Forecast	$187.72
Low Forecast	$109.00

According to the 18 analysts' twelve-month price targets for Sarepta Therapeutics, the average price target is $187.72. The highest price target for SRPT is $235.00, while the lowest price target for SRPT is $109.00. The average price target represents a forecasted upside of 30.15% from the current price of $144.24.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	11 Buy rating(s)	14 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$187.72	$185.06	$156.60	$169.81
Forecasted Upside	30.15% Upside	29.49% Upside	29.55% Upside	29.69% Upside

Get Sarepta Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto Swap Profits

625,000% Gain

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

SRPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SRPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sarepta Therapeutics Stock vs. The Competition

Type	Sarepta Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	30.15% Upside	3,123.51% Upside	9.18% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/1/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$205.00 ➝ $205.00	+27.16%
6/27/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$235.00 ➝ $235.00	+49.77%
6/26/2024	Citigroup 3 of 5 stars	D. Hoang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$172.00 ➝ $176.00	+11.35%
6/24/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	In-Line ➝ In-Line	$139.00 ➝ $185.00	+11.78%
6/24/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$165.00 ➝ $230.00	+43.11%
6/24/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$170.00 ➝ $200.00	+24.44%
Get the Latest News and Ratings for SRPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
6/21/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$165.00 ➝ $165.00	+1.17%
6/21/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$128.00 ➝ $128.00	-23.29%
6/21/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$185.00 ➝ $226.00	+37.54%
6/21/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$166.00 ➝ $213.00	+72.47%
6/21/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$142.00 ➝ $182.00	+47.37%
6/21/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$170.00 ➝ $200.00	+61.94%
5/17/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$145.00 ➝ $179.00	+34.85%
5/14/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$180.00	+36.67%
5/3/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$177.00 ➝ $175.00	+30.93%
3/1/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$164.00 ➝ $167.00	+32.58%
2/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$224.00	+71.29%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$109.00	+24.27%
5/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$151.00 ➝ $141.00	+7.34%
4/26/2023	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$185.00	+50.05%
3/22/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$125.00 ➝ $175.00	+33.41%
3/1/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$171.00 ➝ $190.00	+28.59%
1/11/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$114.00 ➝ $125.00	+4.93%
12/22/2022	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$125.00 ➝ $160.00	+21.76%
8/3/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$100.00 ➝ $122.00	+26.90%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:36 AM ET.

SRPT Forecast - Frequently Asked Questions

What is Sarepta Therapeutics' forecast for 2024?: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Sarepta Therapeutics is $187.72, with a high forecast of $235.00 and a low forecast of $109.00.
Should I buy or sell Sarepta Therapeutics stock right now?: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SRPT shares.
Does Sarepta Therapeutics's stock price have much upside?: According to analysts, Sarepta Therapeutics's stock has a predicted upside of 31.46% based on their 12-month stock forecasts.
Has Sarepta Therapeutics been upgraded or downgraded by Wall Street analysts recently?: Over the previous 90 days, Sarepta Therapeutics's stock had 1 upgrade and 1 downgrade by analysts.
What analysts cover Sarepta Therapeutics?: Sarepta Therapeutics has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, and SVB Leerink in the past 90 days.
Do Wall Street analysts like Sarepta Therapeutics more than its competitors?: Analysts like Sarepta Therapeutics more than other "medical" companies. The consensus rating score for Sarepta Therapeutics is 2.78 while the average consensus rating score for "medical" companies is 2.72. Learn more on how SRPT compares to other companies.